COMPANY

Boston Immune Technologies and Therapeutics

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $990K (SBIR Phase II 5R44AI179385-03, continuation, notice Jun 1, 2026). NIH RePORTER 5R44AI179385-03 (Jun 1, 2026)
Evidence (1 event)
- Jun 1, 2026 · NIH RePORTER 5R44AI179385-03
  Organization: BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.; City/State: WINCHESTER, MA; Project number: 5R44AI179385-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 990243; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 1, 2026 Grant Government grant — SBIR: $990,243 (annual award, as published), announced Jun 1, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 11, 2025 Grant Government grant — SBIR: $2.41M (annual award, as published), announced Jul 11, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Feb 13, 2025 Grant Government grant — SBIR: $926,858 (annual award, as published), announced Feb 13, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Last 2 years.

Jun 1, 2026 Government grant — SBIR: $990,243 (annual award, as published), announced Jun 1, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 11, 2025 Government grant — SBIR: $2.41M (annual award, as published), announced Jul 11, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Feb 13, 2025 Government grant — SBIR: $926,858 (annual award, as published), announced Feb 13, 2025. Agency: NIH/NIAID. Source: government award database. source ↗